Müller O
J Antimicrob Chemother. 1993 Jun;31 Suppl E:137-46. doi: 10.1093/jac/31.suppl_e.137.
The efficacy and safety of azithromycin and clarithromycin were compared in an open multicentre study involving 380 adult patients with acute otitis media, acute sinusitis, or acute streptococcal pharyngitis or tonsillitis. Patients were assigned randomly to receive azithromycin as a single dose of 500 mg daily for three days, or clarithromycin 250 mg bid for ten days. Overall clinical efficacy was found to be similar in each treatment group at day 10-14, with a satisfactory outcome (cured or improved) in 95% of azithromycin and 96% of clarithromycin patients. Bacteriological efficacy was also similar, with eradication of the pathogen in 94% and 95% of isolates, respectively, in the azithromycin and clarithromycin groups. In otitis media, a satisfactory clinical response was seen in 97% of patients in each treatment group. Azithromycin therapy resulted in a clinical response rate of 93% in sinusitis patients, with bacteriological eradication in 93% of patients. Two patients (who were cured clinically) had persistent pathogens. Similarly, clarithromycin achieved clinical response and bacteriological eradication in 95% and 92% of sinusitis patients, respectively. Pathogens persisted in two patients with clinical cure, and in one case of clinical failure. In pharyngitis or tonsillitis, Streptococcus pyogenes was eradicated successfully in 95% of patients in both groups, and the clinical success rates were 96% and 97% for azithromycin and clarithromycin, respectively. No case of clinical failure was associated with persistence of S. pyogenes infection. At the follow-up assessment of this diagnosis group, reinfection had occurred in three (8%) azithromycin patients and one (3%) clarithromycin patient, and all but one patient remained asymptomatic. Both drugs were well-tolerated, with 8.4% of patients on azithromycin and 7.4% on clarithromycin reporting adverse events, mainly gastrointestinal. It was concluded that a three-day course of azithromycin was as effective and well-tolerated as a ten-day course of clarithromycin in adults with acute upper respiratory tract infections.
在一项开放性多中心研究中,对阿奇霉素和克拉霉素的疗效及安全性进行了比较,该研究纳入了380例患有急性中耳炎、急性鼻窦炎、急性链球菌性咽炎或扁桃体炎的成年患者。患者被随机分配,分别接受阿奇霉素每日单次剂量500mg,连用三天,或克拉霉素250mg,每日两次,连用十天。在第10 - 14天,各治疗组的总体临床疗效相似,阿奇霉素组95%的患者和克拉霉素组96%的患者获得了满意的结果(治愈或好转)。细菌学疗效也相似,阿奇霉素组和克拉霉素组分别有94%和95%的分离株病原体被清除。在中耳炎患者中,各治疗组97%的患者有满意的临床反应。阿奇霉素治疗使鼻窦炎患者的临床反应率达到93%,93%的患者细菌学清除,有两名患者(临床治愈)病原体持续存在。同样,克拉霉素在鼻窦炎患者中的临床反应率和细菌学清除率分别为95%和92%。有两名临床治愈患者的病原体持续存在,还有一例临床治疗失败。在咽炎或扁桃体炎患者中,两组95%的患者成功清除了化脓性链球菌,阿奇霉素组和克拉霉素组的临床成功率分别为96%和97%。没有临床治疗失败的病例与化脓性链球菌感染持续存在相关。在该诊断组的随访评估中,三名(8%)接受阿奇霉素治疗的患者和一名(3%)接受克拉霉素治疗的患者发生了再次感染,除一名患者外,其余患者均无症状。两种药物耐受性良好,接受阿奇霉素治疗的患者中有8.4%、接受克拉霉素治疗的患者中有7.4%报告了不良事件,主要是胃肠道方面的。研究得出结论,在患有急性上呼吸道感染的成年人中,三天疗程的阿奇霉素与十天疗程的克拉霉素疗效相当且耐受性良好。